Amneal Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Amneal Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $21. The average 1-year stock price forecast is 16.60% higher than the current stock price, while the lowest is $16 (-11.16%) and the highest is $25 (+38.81%).

Price Target: $21 (+16.60%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$16	$21	$21	$25
Change	-11.16%	+16.60%	+16.60%	+38.81%

Analyst Ratings

The average analyst rating for Amneal Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	2	3	3	2	2	2
Buy	3	2	2	2	2	3
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	4	4	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Chris Schott J.P. Morgan	J.P. Morgan	Buy Maintains $22	Buy	Maintains	$22	+22.15%	Aug 26, 2026
Salveen Richter Goldman Sachs	Goldman Sachs	Buy Maintains $19 → $21	Buy	Maintains	$19 → $21	+16.60%	Aug 10, 2026
Ashwani Verma UBS	UBS	Buy Maintains $23 → $25	Buy	Maintains	$23 → $25	+38.81%	Aug 3, 2026
David Amsellem Piper Sandler	Piper Sandler	Buy Reiterates $17	Buy	Reiterates	$17	-5.61%	Jul 20, 2026
Glen Santangelo Barclays	Barclays	Buy Maintains $16	Buy	Maintains	$16	-11.16%	Jun 11, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.15B

from 3.02B

4.30%

from 3.02B

Revenue Next Year

3.41B

from 3.15B

8.43%

from 3.15B

EPS This Year

1.00

from 0.83

21.01%

from 0.83

EPS Next Year

1.20

from 1.00

19.51%

from 1.00

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	2.09B	2.21B	2.39B	2.79B	3.02B	3.15B
Revenue Growth	5.08%	5.67%	8.20%	16.73%	8.05%	4.30%
Gross Profit	783.95M	791.46M	852.87M	1.02B	1.13B	1.43B
Gross Margin	37.44%	35.78%	35.63%	36.35%	37.38%	45.30%
Operating Income	216.60M	200.03M	260.38M	348.36M	420.70M	713.07M
Net Income	10.62M	-129.99M	-83.99M	-116.89M	72.06M	148.81M
EPS	-	-	-	-	0.83	1.00
EPS Growth	-	-	-	-	43.10%	21.01%
Forward PE	5.65	2.71	11.92	11.69	15.04	17.93
Free Cash Flow	217.65M	120.14M	300.39M	253.45M	197.07M	200.39M
No. Analysts	-	-	-	-	-	3

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	3.2B
Avg	3.1B
Low	3.1B

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	5.3%
Avg	4.3%
Low	3.2%

EPS Forecast

Chart

EPS	2026	2027	2028
High	1.03
Avg	1.00
Low	0.94

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	24.1%
Avg	21.0%
Low	13.1%